Jefferies London Healthcare Conference 2025 November 19, 2025 11:30 AM ESTCompany ParticipantsRuxandra Draghia-Akli - Executive VP ...

Shah Capital increased its stake to about 8.3% and said the gap between Novavax’s scientific potential and its commercial ...

Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, including a ...

Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the third quarter ended ...

(Reuters) -Novavax beat Wall Street expectations for third-quarter revenue on Thursday, helped by milestone payments tied to ...

Novavax on Thursday provided preliminary adjusted revenue for 2026 and pushed back its profitability target by a year to 2028 as the biotech awaits key product launches from its partnership with ...

Shares of Novavax have come under renewed scrutiny as analysts update their fair value estimates in light of recent strategic shifts. The consensus analyst price target for Novavax stock has edged ...

Novavax has raised its 2025 revenue framework by $25 million at the midpoint, projecting adjusted total revenue between $1.040 billion and $1.060 billion. This update reflects the company’s confidence ...

Analysts expect Novavax to report an earnings per share (EPS) of $-0.96. Anticipation surrounds Novavax's announcement, with investors hoping to hear about both surpassing estimates and receiving ...

Gaithersburg-based Novavax raised its annual revenue forecast, banking on milestone payments from vaccine supply and licensing deals.

Novavax raised its full-year 2025 revenue framework, now expecting adjusted total revenue between $1.04 billion and $1.06 ...

Shares of Novavax Inc. NVAX shed 1.94% to $7.06 Thursday, on what proved to be an all-around grim trading session for the ...